Early research (Phase 1)Ended earlyNCT02964507
What this trial is testing
Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Participants With Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced or Metastatic Breast Cancer
Who this might be right for
Neoplasms
GlaxoSmithKline 124